ICU-Associated Costs during the Fourth Wave of the COVID-19 Pandemic in a Tertiary Hospital in a Low-Vaccinated Eastern European Country

Mihai Popescu, Oana Mara Ştefan, Mihai Ştefan, Liana Văleanu and Dana Tomescu
Additional contact information
Mihai Popescu: Department of Anaesthesia and Intensive Care, Fundeni Clinical Institute, “Carol Davila” University of Medicine and Pharmacy, 022328 Bucharest, Romania
Oana Mara Ştefan: Department of Anaesthesia and Intensive Care, Fundeni Clinical Institute, 022328 Bucharest, Romania
Mihai Ştefan: Department of Anaesthesia and Intensive Care, “C. C. Iliescu” Emergency Institute for Cardiovascular Disease, 022328 Buchares, Romania
Liana Văleanu: Department of Anaesthesia and Intensive Care, “C. C. Iliescu” Emergency Institute for Cardiovascular Disease, 022328 Buchares, Romania
Dana Tomescu: Department of Anaesthesia and Intensive Care, Fundeni Clinical Institute, “Carol Davila” University of Medicine and Pharmacy, 022328 Bucharest, Romania

IJERPH, 2022, vol. 19, issue 3, 1-11

Abstract: The COVID-19 pandemic has been associated with a tremendous financial and social impact. The pressure on healthcare systems worldwide has increased with each pandemic wave. The present study assesses the impact of the COVID-19 pandemic on healthcare-derived costs of critically ill patients during the fourth wave of the COVID-19 pandemic in a tertiary hospital in Romania. We prospectively included patients admitted to a single-centre intensive care unit (ICU) during the fourth wave of the COVID-19 pandemic. Median daily costs were calculated from financial records and divided in three groups: administrative costs, treatment costs and investigation costs. These were then compared to two retrospective cohorts of non-COVID-19 patients admitted to the same ICU during the same time interval in 2020 and 2019. Demographic data and the management of SARS-CoV-2 infection and of associated organ dysfunctions were recorded to identify risk factors for higher costs. Our results show that the COVID-19 pandemic has been associated with a 70.8% increase in total costs compared to previous years. This increase was mainly determined by an increase in medication and medical-device-related costs. We identified the following as risk factors for increased costs: higher degrees of lung involvement, severity of respiratory dysfunction, need for renal replacement therapy and the use of antiviral or immunomodulatory therapy. Costs were higher in patients who had a shorter duration of hospitalization. In conclusion, the COVID-19 pandemic is associated with increased costs for patients, and rapid measures need to be taken to ensure adequate financial support during future pandemic waves, especially in developing countries.

Keywords: COVID-19; healthcare-associated costs; intensive care unit; medication costs (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/3/1781/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/3/1781/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:3:p:1781-:d:742214

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().